Belimumab, a BAFF-neutralizing Ab approved by the U.S. Food and Drug Administration for the treatment of systemic lupus erythematosus (SLE) (18), decreases autoAb levels and disease severity (19). Here, TNFSF13B is linked to systemic lupus erythematosus.